ClinicalTrials.Veeva

Menu

The Effects of Contact Lenses With UV/HEV-Filter on Visual Function

Johnson & Johnson (J&J) logo

Johnson & Johnson (J&J)

Status

Completed

Conditions

Visual Acuity

Treatments

Device: ACUVUE OASYS Multifocal
Device: ACUVUE OASYS 1-Day for Astigmatism
Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Device: ACUVUE OASYS MAX 1-Day Multifocal
Device: ACUVUE OASYS MAX 1-Day
Device: ACUVUE OASYS 1-Day

Study type

Interventional

Funder types

Industry

Identifiers

NCT05601544
CR-6480

Details and patient eligibility

About

This is a 2-phase, single-site, non-dispensing, randomized, controlled, double-masked, 2x2 crossover study to objectively measure potential benefits of a new UV/HEV filter using psychophysical testing techniques.

Enrollment

145 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

The subject must:

  1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. Be between 18 and 70 (inclusive) years of age at the time of screening.
  4. By self-report, habitually wear soft contact lenses (sphere, multifocal, toric) in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 5 days per week during the past 30 days.
  5. If applicable, those subjects receiving the spherical lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS
  6. If applicable, those subjects receiving the multifocal lenses will need a vertex-corrected distance refraction within the range of -1.00 through -6.00 DS
  7. If applicable, those subjects receiving the toric lenses will need a vertex-corrected distance refraction within the range of -1.50 through -4.00 DS, -0.625 through -1.625 DC, and cylinder axes: 80/90/100, 170/180/10
  8. The best corrected, monocular, distance visual acuity must be 20/25 or better in each eye

Exclusion criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

The subject must not:

  1. Be currently pregnant or lactating.
  2. Be currently using any ocular medications or have any ocular infection of any type.
  3. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that the investigator believes might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
  4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
  5. Be currently wearing lenses in an extended wear modality.
  6. Have participated in a contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  7. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
  8. (Phase 2 only): Have participated in Phase 1 of the study.
  9. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that the investigator believes might contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
  10. Have a history of strabismus or amblyopia.
  11. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
  12. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

145 participants in 6 patient groups

Sphere TEST/CONTROL
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere TEST/CONTROL sequence.
Treatment:
Device: ACUVUE OASYS 1-Day
Device: ACUVUE OASYS MAX 1-Day
Sphere CONTROL/TEST
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the sphere lenses will be randomized into the sphere CONTROL/TEST sequence.
Treatment:
Device: ACUVUE OASYS 1-Day
Device: ACUVUE OASYS MAX 1-Day
Multifocal TEST/CONTROL
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal TEST/CONTROL sequence.
Treatment:
Device: ACUVUE OASYS MAX 1-Day Multifocal
Device: ACUVUE OASYS Multifocal
Multifocal CONTROL/TEST
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the multifocal lenses will be randomized into the multifocal CONTROL/TEST sequence.
Treatment:
Device: ACUVUE OASYS MAX 1-Day Multifocal
Device: ACUVUE OASYS Multifocal
Toric TEST/CONTROL
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric TEST/CONTROL sequence.
Treatment:
Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Device: ACUVUE OASYS 1-Day for Astigmatism
Toric CONTROL/TEST
Experimental group
Description:
Eligible subjects who are habitual wearers of soft contact lenses that receive the toric lenses will be randomized into the toric CONTROL/TEST sequence.
Treatment:
Device: senofilcon A based contact lens (toric) with new UV/HEV filter
Device: ACUVUE OASYS 1-Day for Astigmatism

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems